Sponsor or institution
Clinical trials and research at Tianjin Medical University Cancer Institute and Hospital
As of November 12, 2026, Find a Trial lists 104 clinical trials run by Tianjin Medical University Cancer Institute and Hospital that are recruiting, in China. 1 was first registered in the last 30 days. By phase: Phase 2 (62), Phase 1 (7), Phase 3 (6), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 104Clinical trials
- 1New in 30 days
- 1Country
Newest trials
All recruiting trials (104)
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
Phase II test of SHR-A1811 for ultra-low HER2 advanced breast cancer
This phase II trial tests SHR-A1811 in women with advanced breast cancer and ultra-low HER2 expression who have had 1-2 prior therapies.
-
Risk-stratified management of inavolisib-induced hyperglycemia in breast cancer patients
This observational study tests whether using a pre-treatment risk-stratified plan to manage high blood sugar from inavolisib helps patients stay on therapy.
-
Stereotactic body radiation therapy for spinal metastases with epidural compression
This study tests whether SBRT can safely help adults with spinal metastases that compress the spinal cord see if the treatment works in reducing issues from their cancer.
-
Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC
This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.
-
Postoperative Edge SBRT for Spinal Metastases
This observational study tests whether high-precision postoperative SBRT with the Edge system can improve local control and neurological outcomes in patients with spinal metastases after surgery.
-
IRE after chemotherapy for locally advanced pancreatic cancer
This study tests whether adding irreversible electroporation after chemotherapy helps people with locally advanced pancreatic cancer who can’t be surgically removed.
-
IRE after targeted immunotherapy in HCC with portal vein tumor thrombus
This study tests whether adding irreversible electroporation (IRE) after a targeted immunotherapy regimen helps people with liver cancer and portal vein tumor thrombus who can’t have surgery.
-
IRE after chemotherapy for locally advanced unresectable perihilar cholangiocarcinoma
This study tests irreversible electroporation plus chemotherapy after induction therapy in adults with unresectable, non-progressing perihilar cholangiocarcinoma to see if local disease control improves.
-
HDR endorectal brachytherapy with 3D-printed guidance and shielding for organ-preserving rectal cancer
This study tests an organ-preserving radiotherapy approach for localized rectal adenocarcinoma in patients who can’t have radical surgery or choose not to, using external beam radiotherapy followed by targeted HDR endorectal brachytherapy with a custom 3D-printed guide and shielding.
-
Enlonstobart with chemotherapy and radiotherapy for locally advanced cervical cancer
This study tests whether adding Enlonstobart to standard chemotherapy and chemoradiotherapy helps patients with locally advanced cervical cancer by increasing response rates and monitoring safety.
-
Immune therapy first or with chemoradiotherapy for unresectable locally advanced esophageal squamous cell cancer
This trial tests whether giving immunotherapy before chemoradiotherapy is more helpful than starting immunotherapy after chemoradiotherapy in people with unresectable locally advanced esophageal squamous cell carcinoma.
-
Sequential Cryoablation, Relatlimab alfa, and Chemotherapy for Bile Duct Tumors
This trial tests whether adding cryoablation before immunotherapy with Relatlimab alfa and chemotherapy can help people with unresectable bile duct cancers.
-
Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan
A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
Postoperative Hypofractionated Radiotherapy for Stage II/III Thymic Epithelial Tumors
This study tests whether giving a shorter course of higher-dose radiotherapy after complete tumor removal is safe for adults with Stage II/III thymic epithelial tumors.
-
Braun junction after pancreatic surgery to see if it helps stomach emptying
This study tests whether adding Braun anastomosis during pancreaticoduodenectomy helps prevent delayed gastric emptying in adults with periampullary tumors.
-
Neoadjuvant EGFR-ADC plus anti-PD-1 therapy for resectable locally advanced hypopharyngeal cancer
This trial tests whether a targeted EGFR-ADC drug plus an anti-PD-1 antibody given before surgery can improve outcomes for adults with resectable locally advanced hypopharyngeal squamous cell carcinoma.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
-
Radiotherapy with GX regimen after high-risk pancreatic cancer surgery
This study tests whether adding a GX-based radiotherapy approach after pancreatic cancer surgery helps prevent recurrence for high-risk patients who had a complete tumor removal.
-
Specialist nurse-led perioperative nursing care for head and neck cancer surgery
A multidisciplinary team of specialist nurses tests whether a nurse-led perioperative care plan improves recovery for people having head and neck cancer surgery.
-
Surgical Total Clearance vs Bile Duct Preservation for Biliary Tract Cancers
This trial tests whether removing the bile duct from the pancreas to the hepatic confluence plus extensive lymph node removal improves outcomes for patients with biliary tract cancer.
-
Short-Course Radiotherapy Followed by Immunotherapy Plus Chemotherapy for Locally Advanced Rectal Cancer
This trial tests whether a short course of radiation followed by immunotherapy and chemotherapy can improve outcomes for adults with MSS locally advanced rectal cancer.
-
Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer
This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.
-
Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery
This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.
-
Sacituzumab tirumotecan plus furmonertinib for advanced EGFR‑mutant non‑squamous lung cancer after EGFR‑TKI and platinum chemotherapy
This Phase II trial will test whether combining sacituzumab tirumotecan with furmonertinib helps people with advanced EGFR‑mutant non‑squamous NSCLC who progressed after EGFR‑TKI and platinum chemotherapy.
-
Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression
This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.
-
Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer
This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.
-
Hippocampus-protective radiotherapy combined with osimertinib for symptomatic brain metastases in EGFR-mutated lung cancer
This trial tests whether hippocampal-sparing whole-brain radiotherapy with a higher-dose simultaneous boost to brain tumors plus daily osimertinib can better control symptomatic brain metastases in people with newly diagnosed EGFR-sensitive non-small cell lung cancer.
-
Neoadjuvant tislelizumab plus lenvatinib for resectable hepatocellular carcinoma at high risk of recurrence
This trial tests whether giving tislelizumab and lenvatinib before surgery can reduce recurrence and improve outcomes in people with resectable hepatocellular carcinoma at high risk of coming back.
-
Neoadjuvant chemoradiotherapy with serplulimab and nimotuzumab for resectable locally advanced esophageal squamous cell carcinoma
This trial will try adding serplulimab and nimotuzumab to preoperative chemoradiotherapy to see if it improves surgical and pathological outcomes for adults with resectable locally advanced esophageal squamous cell carcinoma.
-
Surufatinib with Gemcitabine and Nab-paclitaxel as Neoadjuvant Therapy for High-Risk or Borderline Resectable Pancreatic Cancer
This trial tests whether adding surufatinib to gemcitabine and nab-paclitaxel before surgery helps adults with high-risk resectable or borderline resectable pancreatic cancer.
-
Real-world outcomes of CDK4/6 inhibitors plus hormone therapy for HR+/HER2- advanced breast cancer
This project will see if different CDK4/6 inhibitors combined with endocrine therapy lead to different outcomes and what treatments patients receive next for adults with HR+/HER2- advanced breast cancer treated at Tianjin Medical University Cancer Hospital.
-
CRP regimen for older adults with untreated double‑expressor diffuse large B‑cell lymphoma
This trial will try the CRP drug combination (chidamide, rituximab, and polatuzumab vedotin) as first-line treatment for older adults with previously untreated double-expressor DLBCL.
-
Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response
This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.
-
Bemotuzumab with chemotherapy and anlotinib, then targeted radiotherapy for extensive-stage small cell lung cancer
This phase 2 study tests whether a combination of bemotuzumab, chemotherapy, and anlotinib, followed by continued bemotuzumab and anlotinib with thoracic radiotherapy, can help untreated extensive-stage small cell lung cancer.
-
GK01 with or without chemotherapy after surgical removal of solid tumors
This trial tries GK01, alone or with chemotherapy, after surgery to help people with resectable solid tumors stay cancer-free.
-
Dexmedetomidine nasal spray to improve awake sedation for breast-conserving surgery
This will try a dexmedetomidine nasal spray before breast-conserving surgery in women with breast cancer to provide calm sedation during the operation and help them wake up smoothly afterwards.
-
Serplulimab with chemoradiotherapy, with or without extra chemotherapy, for locally advanced cervical cancer
This trial tests whether adding induction and consolidation chemotherapy to serplulimab plus concurrent chemoradiotherapy helps women with untreated locally advanced cervical cancer stay cancer-free longer.
-
Anrikefon Injection for Postoperative Pain After Laparoscopic Gastrectomy in Gastric Cancer
This trial tests whether Anrikefon given by IV can reduce pain after totally laparoscopic distal gastrectomy for gastric cancer.
-
WAST cell plus docetaxel for PD‑1–resistant advanced non‑small cell lung cancer
This will test whether infusions of WAST immune cells combined with docetaxel chemotherapy can shrink tumors or slow progression in people with advanced NSCLC that stopped responding to PD‑1 inhibitors.
-
Adjuvant L-TIL plus tislelizumab after surgery for resectable NSCLC without pCR
This trial tests whether giving liquid tumor-infiltrating lymphocytes (L-TIL) together with the PD-1 blocker tislelizumab after surgery helps people with resectable stage II–IIIB NSCLC who did not achieve a complete response to pre-surgery chemoimmunotherapy.
-
Fluzoparib maintenance in platinum-sensitive advanced triple-negative breast cancer
This study tests whether continuing Fluzoparib as maintenance therapy helps people with BRCA mutation–associated or non–BRCA-mutant platinum-sensitive advanced TNBC stay disease-free longer.
-
Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for relapsed or refractory neuroblastoma in children
This trial tests a four-drug combination to see if it can control neuroblastoma in children whose disease has come back or not responded to treatment.
-
Furmonertinib plus intrathecal chemotherapy and stereotactic radiotherapy for EGFR‑mutated NSCLC with brain parenchymal and leptomeningeal metastases
This trial tries to see if taking furmonertinib with spinal‑fluid chemotherapy injections and focused brain radiotherapy helps people with EGFR‑mutated lung cancer who have both brain and leptomeningeal metastases.
-
Irinotecan liposome with capecitabine and enronsubemab plus short-course radiotherapy before surgery for locally advanced rectal cancer
This trial will test whether giving irinotecan liposome, capecitabine, and enronsubemab together with a short course of radiotherapy before surgery can better shrink locally advanced rectal cancer.
-
StratifiedToripalimab Consolidation After Chemoimmunotherapy and CCRT in Unresectable ESCC
This trial tests whether giving toripalimab after chemoimmunotherapy and chemoradiation helps people with unresectable locally advanced esophageal squamous cell carcinoma to see if they benefit more than observation.
-
Defining how much No.4sb lymph node to remove for advanced distal stomach cancer
This project will try to find the best range of No.4sb lymph node removal during surgery for people with locally advanced distal stomach cancer.
-
Definitive chemoradiotherapy versus surgery for resectable esophageal squamous cell carcinoma after a good response to preoperative chemo-immunotherapy
This study will test whether definitive concurrent chemoradiotherapy can allow people with resectable esophageal squamous cell carcinoma who respond well after two cycles of chemo-immunotherapy to avoid surgery while maintaining disease control.
-
Tislelizumab with chemotherapy given before surgery in 2 or 4 cycles for locally advanced, resectable head and neck squamous cell cancer
This trial tests whether 2 or 4 cycles of neoadjuvant tislelizumab plus chemotherapy can be given safely and more effectively before surgery.
-
QL1706 (iparomlimab + tuvonralimab) with TACE and lenvatinib for second-line treatment of unresectable intermediate-to-advanced liver cancer
This test will try whether adding QL1706 (iparomlimab plus tuvonralimab) to TACE and lenvatinib helps people with unresectable intermediate-to-advanced hepatocellular carcinoma who progressed after PD-1/PD-L1 plus bevacizumab.
-
Neoadjuvant toripalimab with platinum chemotherapy followed by chemoradiotherapy and toripalimab maintenance for locally advanced cervical cancer
This treatment plan tests whether giving toripalimab with platinum chemotherapy before, during, and after chemoradiotherapy helps women with locally advanced cervical cancer.
-
Lattice radiation combined with immunotherapy for advanced solid tumors
This trial will test whether combining lattice (spatially fractionated) radiation with immunotherapy helps people with advanced or metastatic solid tumors.
-
Fractionated liposomal irinotecan with 5‑FU/LV and bevacizumab for second-line advanced colorectal cancer
This study will test whether giving liposomal irinotecan in split doses together with 5‑FU/LV and bevacizumab helps people with advanced colorectal cancer who need a second-line treatment after oxaliplatin-based therapy.
-
Chemoradiation followed by iparomlimab consolidation for older adults with esophageal squamous cell carcinoma
This trial tests whether giving iparomlimab after standard chemoradiation helps people aged 70 and older with locally advanced esophageal squamous cell carcinoma.
-
Real-time pressure controller to prevent peripheral neuropathy from albumin-bound paclitaxel
This trial will test whether a real-time pressure controller can reduce numbness, tingling, and nerve pain in adults getting albumin-bound paclitaxel for breast cancer.
-
FOLFOX with durvalumab, bevacizumab, and targeted radiation to try to make advanced liver cancer operable
This will try combining liver-directed FOLFOX chemotherapy, durvalumab, bevacizumab, and focused radiation to see if intermediate or advanced liver cancer can be shrunk enough for surgery.
-
Testing GK01 for advanced solid tumors
This study is testing a new treatment called GK01 to see if it can help people with advanced solid tumors who haven't had success with other therapies.
-
QL1706 plus chidamide with gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic cancer
This study will test whether adding QL1706 and chidamide to standard gemcitabine plus nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic adenocarcinoma.
-
Ivonescimab combined with AG regimen for borderline resectable pancreatic cancer
This study is testing if a new treatment combining Ivonescimab with standard therapy can help people with borderline resectable pancreatic cancer get ready for surgery.
-
Cryoablation with Tislelizumab and Chemotherapy for Non-small Cell Lung Cancer
This study is testing if combining a freezing treatment with a new drug and chemotherapy can help people with early-stage lung cancer before surgery and improve their chances of survival.
-
QL1706 therapy for advanced endometrial cancer after PD-1/L1 treatment failure
This study is testing if a new treatment called QL1706, combined with chemotherapy, can help people with advanced endometrial cancer who didn't respond to earlier PD-1/L1 therapy.
-
Evaluating CHT101 for patients with specific blood cancers
This study is testing a new treatment called CHT101 to see if it can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.
-
Combination therapy for advanced triple-negative breast cancer
This study is testing a new combination treatment for people with advanced triple-negative breast cancer who have already tried other therapies to see if it helps them live longer without their cancer getting worse.
-
New treatment for advanced small cell lung cancer
This study is testing a new combination of treatments for people with advanced small cell lung cancer who haven't had success with their first round of chemotherapy.
-
Combination treatment for advanced intrahepatic cholangiocarcinoma and gallbladder cancer
This study is testing a new combination treatment for people with advanced bile duct and gallbladder cancer to see if it can help them respond better to therapy and possibly become eligible for surgery.
-
Targeted high- and low-dose radiation with chemotherapy and immunotherapy for advanced lung cancer
This trial tests whether adding focused high‑dose and low‑dose radiation to chemotherapy and immunotherapy helps people with advanced lung cancer whose disease progressed after prior immunotherapy.
-
Comparing two treatments for inoperable primary liver cancer
This study is testing which treatment works better for people with inoperable primary liver cancer by comparing stereotactic radiosurgery and radiofrequency ablation.
-
Treatment of advanced pancreatic cancer using CHT102
This study is testing a new CAR-T cell therapy called CHT102 to see if it can safely help people with advanced pancreatic cancer.
-
Treatment of advanced solid tumors using CD70-targeting CAR-T cells
This study is testing a new CAR-T cell therapy that targets a specific protein in advanced solid tumors to see if it can help patients with these cancers feel better.
-
Combining Serplulimab with Chemoradiotherapy for High-Risk Postoperative Cervical Cancer
This study is testing if adding the immunotherapy drug Serplulimab to standard chemoradiotherapy can help women with high-risk cervical cancer feel better after surgery.
-
Combining toripalimab with GemCis for treating resectable intrahepatic cholangiocarcinoma
This study is testing if combining a new drug called toripalimab with standard chemotherapy can help people with resectable intrahepatic cholangiocarcinoma do better before surgery.
-
Evaluating CHT102 for treating advanced solid tumors with mesothelin expression
This study is testing a new immune therapy called CHT102 to see if it can help adults with advanced solid tumors that have the mesothelin protein and haven't responded to other treatments.
-
Radiation and Tiselizumab with RCHOP for Bulky Follicular Lymphoma
This study is testing if adding radiation to a combination of Tiselizumab and R-CHOP chemotherapy can help people with bulky follicular lymphoma feel better and improve their treatment results.
-
Investigating serum ferritin as a biomarker for immune-related adverse events
This study is testing if a blood marker called serum ferritin can help doctors identify and predict immune-related side effects in patients with cancer receiving different types of treatment.
-
Combining Glofitamab and Chidamide for treating recurrent DLBCL
This study is testing if a combination of two medications, Glofitamab and Chidamide, can help adults with recurring diffuse large B-cell lymphoma feel better.
-
Combination treatment for advanced gastric cancer with HER2 overexpression
This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.
-
Combination of adebrelimab and XELOX for treating advanced gastric cancer before surgery
This study is testing if combining a new immune treatment with chemotherapy can help people with advanced stomach cancer live longer and have fewer recurrences after surgery.
-
Skipping breast surgery after complete response to pre-surgery chemo and radiation
This trial tests whether people with triple-negative or HER2‑positive early breast cancer who have a complete clinical response to pre-surgery chemotherapy plus radiation can safely skip breast surgery.
-
Dalpiciclib Plus Toremifene as First-Line Maintenance in HR-Positive, HER2-Negative Metastatic Breast Cancer
This study tests whether combining dalpiciclib with toremifene can help postmenopausal or eligible premenopausal women with newly diagnosed advanced HR-positive, HER2-negative breast cancer see if their disease responds and lasts longer.
-
AK112 combined with chemotherapy for advanced esophageal cancer
This study is testing if a new drug called AK112, when combined with chemotherapy, can help people with advanced esophageal cancer who haven't had treatment before.
-
Treatment for advanced solid tumors using engineered T cells
This study is testing a new treatment using specially designed T cells to see if it can help people with advanced solid tumors that haven't responded to other therapies.
-
Combination treatment for untreated Mantle Cell Lymphoma patients
This study is testing a new combination treatment without chemotherapy for people with untreated Mantle Cell Lymphoma to see if it can improve their health and survival.
-
Combination treatment for metastatic pancreatic cancer
This study is testing a new combination of treatments for people with metastatic pancreatic cancer to see if it can help their immune system fight the cancer better.
-
Induction immunochemotherapy followed by chemoradiotherapy for advanced esophageal squamous cell carcinoma
This plan will try two cycles of induction immunochemotherapy and then give chemoradiotherapy—adding the immunotherapy drug adebrelimab during radiation for patients who respond—to treat people with unresectable locally advanced esophageal squamous cell carcinoma.
-
Using NEPA to prevent nausea and vomiting after gastrointestinal cancer surgery
This study is testing if a new medication can help prevent nausea and vomiting after surgery for patients with gastrointestinal cancer.
-
Treatment for relapsed or refractory B-cell non-Hodgkin lymphoma using dual-targeted cells
This study is testing a new treatment called LUCAR-G39D to see if it can help adults with relapsed or hard-to-treat B-cell non-Hodgkin lymphoma feel better.
-
Combining osimertinib and dalpiciclib for advanced lung cancer after treatment resistance
This study is testing if combining two drugs, osimertinib and dalpiciclib, can help people with advanced lung cancer who have not responded to other treatments.
-
Anlotinib after surgery for non-pCR non-small cell lung cancer
This will test whether taking anlotinib capsules after surgery helps people with stage IIA–IIIA non-small cell lung cancer who did not have a complete pathological response after preoperative chemo‑immunotherapy.
-
Combining rituximab with prior therapies for advanced liver cancer
This study is testing if adding rituximab to other treatments can help people with advanced liver cancer who haven't had success with previous therapies.
-
Microwave ablation and artery occlusion for treating secondary hypersplenism
This study is testing a new treatment that combines microwave heat and blocking a blood vessel to help people with severe hypersplenism related to cirrhosis who haven't found relief with standard therapies.
-
Toripalimab treatment for high-risk early-stage lung cancer after surgery
This study is testing if the immunotherapy drug Toripalimab can help prevent lung cancer from coming back in patients who have just had surgery for early-stage non-small cell lung cancer.
-
Investigating immune therapy for advanced head and neck cancer after initial treatment
This study is testing a new immune therapy combined with radiation and chemotherapy to see if it can help people with advanced head and neck cancer who have responded well to initial treatment.
-
Combining TQB2450 injection with Anlotinib and chemotherapy for advanced lung cancer
This study is testing if adding a new injection called TQB2450 to Anlotinib and chemotherapy can help people with advanced lung cancer who haven't responded to earlier treatments.
-
Breast reconstruction using TiLOOP Mesh or not
This study is testing if using a special mesh during breast reconstruction helps women feel better and have better results after surgery compared to not using the mesh.
-
Osimertinib treatment after surgery for high-risk stage I lung cancer
This study is testing if taking Osimertinib after surgery can help people with high-risk stage I lung cancer stay cancer-free longer.
-
Using Pemigatinib for Advanced Gastrointestinal Cancer with FGFR Alterations
This study is testing if a drug called Pemigatinib can help people with advanced gastrointestinal cancer that has certain genetic changes and hasn't worked with other treatments.
-
Durvalumab with chemotherapy before surgery for biliary tract cancer
This phase II trial tests a combination of durvalumab with gemcitabine, cisplatin, and nab-paclitaxel before surgery in people with resectable biliary tract cancer to see if it helps shrink tumors and improve outcomes.
-
Combining albumin-bound paclitaxel with gemcitabine for treating inoperable pancreatic cancer
This study is testing if giving a combination of two cancer drugs, albumin-bound paclitaxel and gemcitabine, every three weeks can help people with inoperable pancreatic cancer just as well as giving them every four weeks.
-
Combining PD-1 antibody with chemotherapy for advanced gastric cancer treatment
This study is testing whether combining a PD-1 antibody with a specific chemotherapy treatment can help people with advanced stomach cancer before and after surgery.
-
Comparing total and partial omentectomy for advanced gastric cancer
This study is testing whether keeping the omentum during surgery for advanced gastric cancer can help patients live as long as those who have it removed.
-
Combining pembrolizumab with chemotherapy for esophageal cancer treatment
This study is testing if combining a drug called pembrolizumab with chemotherapy can help people with advanced esophageal cancer live longer and have better outcomes before surgery compared to standard treatment.
-
Comparing two surgical approaches for early-stage lung cancer with ground-glass nodules
This study is testing which of two surgical methods is better for people with early-stage lung cancer that has ground-glass nodules, to see which one helps them live longer and stay cancer-free.
Quick answers
How many clinical trials run by Tianjin Medical University Cancer Institute and Hospital are recruiting right now?
104, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 62, Phase 1: 7, Phase 3: 6, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.